S16 E07 Expanding Market Access and Innovative Medicines
National Pharmaceutical Congress (NPC) PodcastShow Notes
Country General Manager of Alnylam Pharmaceuticals’ Colleen Coxson discusses compliance and self-regulation, the potential for siRNA on Alzheimer’s, and the future of drug development.
Get full access to NPC Healthbiz Weekly at healthbiz.substack.com/subscribe
More from National Pharmaceutical Congress (NPC) Podcast
CEO and co-founder of Celystra Pharma’s Paul Levesque discusses Canadian biotech, rare disease policy, and AI as a healthcare accelerator.
General Manager of UCB Canada’s Rodrigo Reis discusses patient-centric innovation, authentic sustainability, and strengthening digital capabilities.
Associate Vice-President and GM of Incyte’s Chris White discusses Most Favoured Nation pricing impacts, drug access and reimbursement, and wildly authentic leadership.
Founder of Brighthive Innovation Group’s Leandra Wells discusses tech enablement, transforming organization on lean budgets, and prioritizing healthcare in Canada.
CEO of Bloom Burton’s Brian Bloom discusses the themes of the 2025 Bloom Burton conference, return entrepreneurs in the Canadian Life Sciences landscape, and accelerating drug discovery with AI.